Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Epple

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonistsMihai Azimioara, Phil Alper, Christopher Cow, et al.
ACS Medicinal Chemistry Letters|December 17, 2021
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine RET InhibitorsCasey J N Mathison, Yang Yang, John Nelson, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Efficacy and Tolerability of Pyrazolo[1,5-<i>a</i>]pyrimidine RET Kinase Inhibitors for the Treatment of Lung AdenocarcinomaCasey J N Mathison, Donatella Chianelli, Paul V Rucker, et al.
Nature Communications|November 12, 2021
Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathyMatthias Kettwig, Katharina Ternka, Kristin Wendland, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|August 1, 2006
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethersDavid C Tully, Hong Liu, Arnab K Chatterjee, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonistsMihai Azimioara, Phil Alper, Christopher Cow, et al.
ACS Medicinal Chemistry Letters|December 17, 2021
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine RET InhibitorsCasey J N Mathison, Yang Yang, John Nelson, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Efficacy and Tolerability of Pyrazolo[1,5-<i>a</i>]pyrimidine RET Kinase Inhibitors for the Treatment of Lung AdenocarcinomaCasey J N Mathison, Donatella Chianelli, Paul V Rucker, et al.
Nature Communications|November 12, 2021
Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathyMatthias Kettwig, Katharina Ternka, Kristin Wendland, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Pageof 3